핵의학

본문글자크기
  • [Sci Rep.] Predictive and Prognostic Value of 18F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer.

    [Sci Rep.] Predictive and Prognostic Value of 18F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer.

    성균관의대 / 문승환, 선종무, 최준영*

  • 출처
    Sci Rep.
  • 등재일
    2019 Aug 21
  • 저널이슈번호
    9(1):12215. doi: 10.1038/s41598-019-48674-4.
  • 내용

    바로가기  >

    그림.1 FDG PET/CT로 측정한 종양 TLG와 치료반응과의 관계.

     

    Abstract
    We investigated the relationship between tumor 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography/computed tomography (PET/CT) scans and thymidylate synthase (TS) expression. In addition, we evaluated the value of FDG uptake in predicting treatment response and prognosis when combined with TS expression in patients with advanced non-small cell lung cancer (NSCLC). We measured the maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis (TLG) of tumor lesions on pretreatment scan in 234 patients (age: 60.1 ± 9.4 years; males: 56.4%) with stage IV non-squamous NSCLC who were enrolled in the prospective phase II clinical trial. We investigated the correlation of the parameters with TS expression and the predictive values of the parameters compared with other clinical factors. Among these parameters, TLG was the most relevant parameter that had a significant correlation with TS expression (ρ = 0.192, P = 0.008). A multivariable Cox proportional-hazards model revealed that high TLG was a significant independent predictor for treatment response (hazard ratio [HR]: 2.05; P = 0.027), progression-free survival (HR: 1.39; P = 0.043), and overall survival (HR: 1.65; P = 0.035) with other factors. In patients with advanced non-squamous NSCLC, tumor TLG on pretreatment PET/CT scan has predictive and prognostic value.

     


    Author information

    Moon SH1, Sun JM2, Ahn JS2, Park K2, Kim BT1, Lee KH1, Ahn MJ2, Choi JY3.
    1
    Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
    2
    Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
    3
    Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. jynm.choi@samsung.com.

  • 연구소개
    비소세포성 폐암의 치료 표적 중 하나인 thymidylate synthase 발현도가 종양의 FDG 섭취정도와 관계가 있고, FDG 섭취정도는 항암제에 대한 치료반응 및 예후 예측에도 도움이 된다는 연구입니다.
  • 덧글달기
    덧글달기
       IP : 34.201.122.150

    등록